Innate Pharma receives $5M from its Monster-deal with BMS

14/10/2015 - 2 minutes

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011.

This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or high-risk untreated Chronic Lymphocytic Leukemia (CLL).

This milestone marks the start of a new Phase II trial of lirilumab in hemato-oncology outside of Acute Myeloid Leukemia. We are pleased with the broad clinical program for lirilumab, and expect that results will begin to be delivered in 2016” – Hervé Brailly, CEO and co-founder of Innate Pharma.

In total, 6 trials are currently being performed with lirilumab, testing a range of solid and hematological cancer indications, multiple rationales and combinations with cytotoxic antibodies, and checkpoint inhibitors in chemotherapy.

Even if it is a small payment (form the biotech industry’s perspective,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: